A Phase 2 interventional study of Placebo and PF-06700841 15 mg in Systemic Lupus Erythematosus, sponsored by Pfizer. Completed at 164 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 60th largest by enrollment of the 407 interventional ones that give a count, is one of 19 that started in 2019, is one of 120 in phase 2, and was the 282nd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
PF-06700841 15 mg
Drug: PF-06700841 15 mg
PF-06700841 30 mg
Drug: PF-06700841 30 mg
PF-06700841 45 mg
Drug: PF-06700841 45 mg
Placebo
PF-06700841 15 mg
PF-06700841 30 mg
PF-06700841 45 mg
Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52
SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point increase) in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
Time frame: Week 52
Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52
BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
Time frame: Week 52
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52
LLDAS was defined as SLE disease activity index (SLEDAI-2k \<=4, with no activity in major organ systems \[renal, central nervous system, cardiopulmonary, vasculitis, fever\]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity) \<=1; a current prednisolone (or equivalent) dose \<=7.5 milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
Time frame: Week 52
Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline
In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to \<=7.5 mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52).
Time frame: Week 52 for achieving reduction in dose along with Week 40 to Week 52 for sustained dosing
Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline
In this outcome measure data is reported for participants who achieved a reduction in SRI-4 response with prednisone dose reduced to \<=7.5 mg/day and sustained for 12 weeks at Week 52.
Time frame: 12 Weeks prior at Week 52 (Week 40 to Week 52)
Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10
CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).
Time frame: Week 52
Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52
The FACIT-F Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).
Time frame: Baseline, Week 52
Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Pain Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Planning Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
Time frame: Baseline, Week 52
Incidence Rate of Severe Flare Event
Incidence rate was defined as the number of new events per 100 person-years.
Time frame: Week 52
Number of Participants With Treatment-Emergent Adverse Events (AE)
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs.
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Number of Participants With Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Number of Participants With Adverse Events Leading to Discontinuation From Study
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this outcome measure, participants with adverse events leading to discontinuation from study were reported.
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Number of Participants With Clinically Significant Vital Signs Abnormalities
Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator.
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Clinical significance in ECG abnormalities was judged by investigator.
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Number of Participants With Laboratory Test Abnormalities
Hematology (Hemoglobin\[hgb\], hematocrit, erythrocytes\[ery\]:\<0.8\*lower limit of normal\[LLN\];reticulocytes, reticulocytes/ery:\<0.5\*LLN,\>1.5\*upper LN\[ULN\];ery mean corpuscular volume\[EMC\], EMC hgb:\<0.9\*LLN,\>1.5\*ULN;EMC hgb concentration:\<0.9\* LLN;platelet:\<0.5\*LLN;leukocytes\[leu\]:\<0.6\*LLN,\>1.5\*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:\<0.8\* LLN,\>1.2\*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:\>1.2\*ULN;activated partial thromboplastin time\[PTT\], PTT, prothrombin time:\>1.1\*ULN);Clinical chemistry (Total/direct/indirect bilirubin, glucose-fasting:\>1.5\*ULN; aspartate aminotransferase\[AT\], alanine AT:\>3.0\*ULN; protein, albumin, HDL cholesterol:\<0.8\*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:\>1.3\*ULN;urate, LDL cholesterol:\>1.2\*ULN;potassium:\<0.9\*LLN,\>1.1\*ULN;calcium, bicarbonate:\<0.9\*LLN;creatine kinase:\>2.0\*ULN);Urinalysis (pH\<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase, granular/hyaline/WBCs casts:\>1).
Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
A total of 350 participants with active systemic lupus erythematosus (SLE) were enrolled and randomized in the study.
| Milestone | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Started | 100 | 50 | 101 | 99 |
| Completed | 68 | 36 | 78 | 71 |
| Not completed | 32 | 14 | 23 | 28 |
| Withdrew: Adverse event | 12 | 7 | 10 | 17 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 8 | 1 | 3 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 |
| Withdrew: Physician's decision | 0 | 0 | 1 | 0 |
| Withdrew: Site terminated by sponsor | 2 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 6 | 6 | 5 |
| Milestone | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Started | 100 | 50 | 101 | 99 |
| Completed | 89 | 42 | 89 | 92 |
| Not completed | 11 | 8 | 12 | 7 |
| Withdrew: Adverse event | 4 | 2 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 | 0 |
| Withdrew: Physician's decision | 0 | 0 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 5 | 7 | 1 |
SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point increase) in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52 | 64.6 (54.5 to 74.7) | 57.4 (42.2 to 72.6) | 69.7 (60.1 to 79.3) | 66.3 (56.1 to 76.5) |
BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52 | 43.8 (33.3 to 54.2) | 42.6 (27.4 to 57.8) | 52.5 (42.2 to 62.9) | 53.3 (42.5 to 64.0) |
LLDAS was defined as SLE disease activity index (SLEDAI-2k \<=4, with no activity in major organ systems \[renal, central nervous system, cardiopulmonary, vasculitis, fever\]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity) \<=1; a current prednisolone (or equivalent) dose \<=7.5 milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52 | 22.6 (13.5 to 31.6) | 21.3 (8.5 to 34.0) | 35.1 (25.0 to 45.1) | 34.1 (23.6 to 44.6) |
In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to \<=7.5 mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52).
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline | 26.4 (13.6 to 39.2) | 36.4 (18.4 to 54.3) | 37.0 (21.9 to 52.0) | 41.9 (26.0 to 57.8) |
In this outcome measure data is reported for participants who achieved a reduction in SRI-4 response with prednisone dose reduced to \<=7.5 mg/day and sustained for 12 weeks at Week 52.
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline | 20.8 (8.9 to 32.6) | 30.3 (13.1 to 47.5) | 32.6 (18.0 to 47.2) | 32.6 (17.4 to 47.7) |
CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).
| Percentage of participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10 | 73.9 (53.8 to 94.0) | 58.3 (26.3 to 90.4) | 77.8 (60.2 to 95.3) | 56.3 (28.8 to 83.7) |
The FACIT-F Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52 | 4.6 (2.5 to 6.6) | 7.4 (4.5 to 10.2) | 5.8 (3.8 to 7.8) | 7.6 (5.5 to 9.7) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52 | 11.585 (7.475 to 15.695) | 10.892 (5.241 to 16.544) | 12.371 (8.464 to 16.278) | 14.875 (10.748 to 19.002) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52 | 8.113 (4.132 to 12.093) | 10.469 (4.968 to 15.969) | 7.547 (3.749 to 11.346) | 11.823 (7.806 to 15.840) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52 | 9.207 (4.352 to 14.062) | 10.935 (4.070 to 17.799) | 8.169 (3.448 to 12.890) | 15.599 (10.355 to 20.843) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Pain Domain Scores of LupusQoL at Week 52 | 15.065 (10.470 to 19.659) | 15.480 (9.132 to 21.828) | 16.855 (12.488 to 21.223) | 24.418 (19.790 to 29.047) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Planning Domain Scores of LupusQoL at Week 52 | 14.168 (9.423 to 18.912) | 12.013 (5.487 to 18.538) | 10.335 (5.826 to 14.843) | 20.310 (15.523 to 25.097) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52 | 10.317 (5.951 to 14.683) | 11.893 (5.892 to 17.894) | 11.701 (7.550 to 15.853) | 16.443 (12.036 to 20.850) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52 | 12.430 (6.842 to 18.019) | 12.625 (4.112 to 21.139) | 6.494 (0.960 to 12.027) | 15.363 (9.078 to 21.647) |
The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.
| Units on a scale | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52 | 12.535 (7.227 to 17.842) | 17.739 (10.412 to 25.065) | 11.560 (6.500 to 16.621) | 18.878 (13.523 to 24.233) |
Incidence rate was defined as the number of new events per 100 person-years.
| Events per 100 person-years | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Incidence Rate of Severe Flare Event | 8.32 (3.35 to 17.15) | 6.92 (1.43 to 20.23) | 3.24 (0.67 to 9.46) | 6.95 (2.55 to 15.13) |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs.
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AE) | 80 | 38 | 88 | 83 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 8 | 4 | 8 | 9 |
An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this outcome measure, participants with adverse events leading to discontinuation from study were reported.
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation From Study | 6 | 2 | 1 | 3 |
Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator.
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 | 0 | 0 |
Clinical significance in ECG abnormalities was judged by investigator.
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 |
Hematology (Hemoglobin\[hgb\], hematocrit, erythrocytes\[ery\]:\<0.8\*lower limit of normal\[LLN\];reticulocytes, reticulocytes/ery:\<0.5\*LLN,\>1.5\*upper LN\[ULN\];ery mean corpuscular volume\[EMC\], EMC hgb:\<0.9\*LLN,\>1.5\*ULN;EMC hgb concentration:\<0.9\* LLN;platelet:\<0.5\*LLN;leukocytes\[leu\]:\<0.6\*LLN,\>1.5\*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:\<0.8\* LLN,\>1.2\*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:\>1.2\*ULN;activated partial thromboplastin time\[PTT\], PTT, prothrombin time:\>1.1\*ULN);Clinical chemistry (Total/direct/indirect bilirubin, glucose-fasting:\>1.5\*ULN; aspartate aminotransferase\[AT\], alanine AT:\>3.0\*ULN; protein, albumin, HDL cholesterol:\<0.8\*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:\>1.3\*ULN;urate, LDL cholesterol:\>1.2\*ULN;potassium:\<0.9\*LLN,\>1.1\*ULN;calcium, bicarbonate:\<0.9\*LLN;creatine kinase:\>2.0\*ULN);Urinalysis (pH\<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase, granular/hyaline/WBCs casts:\>1).
| Participants | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 96 | 48 | 99 | 97 |
Collected over Day 1 of dosing up to 4 weeks after last dose of study drug (maximum up to 56 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/100 (0%) | 8/100 (8%) | 47/100 (47%) |
| PF-06700841 15 mg | 0/50 (0%) | 4/50 (8%) | 19/50 (38%) |
| PF-06700841 30 mg | 1/101 (1%) | 8/101 (7.9%) | 53/101 (52.5%) |
| PF-06700841 45 mg | 1/99 (1%) | 9/99 (9.1%) | 47/99 (47.5%) |
| Event | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 2/100 | 0/50 | 1/101 | 2/99 |
| GastroenteritisInfections and infestations | 0/100 | 1/50 | 0/101 | 0/99 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/100 | 1/50 | 0/101 | 0/99 |
| Thalamic strokeNervous system disorders | 0/100 | 1/50 | 0/101 | 0/99 |
| Lupus pleurisyRespiratory, thoracic and mediastinal disorders | 0/100 | 1/50 | 0/101 | 0/99 |
| HypersensitivityImmune system disorders | 0/100 | 0/50 | 1/101 | 1/99 |
| BacteraemiaInfections and infestations | 0/100 | 0/50 | 0/101 | 1/99 |
| COVID-19Infections and infestations | 0/100 | 0/50 | 1/101 | 1/99 |
| COVID-19 pneumoniaInfections and infestations | 0/100 | 0/50 | 0/101 | 1/99 |
| Transaminases increasedInvestigations | 0/100 | 0/50 | 0/101 | 1/99 |
| Event | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg |
|---|---|---|---|---|
| COVID-19Infections and infestations | 17/100 | 9/50 | 11/101 | 10/99 |
| HeadacheNervous system disorders | 5/100 | 4/50 | 17/101 | 9/99 |
| Urinary tract infectionInfections and infestations | 11/100 | 1/50 | 10/101 | 11/99 |
| Upper respiratory tract infectionInfections and infestations | 7/100 | 1/50 | 11/101 | 8/99 |
| NasopharyngitisInfections and infestations | 7/100 | 5/50 | 6/101 | 8/99 |
| NauseaGastrointestinal disorders | 5/100 | 4/50 | 3/101 | 7/99 |
| DiarrhoeaGastrointestinal disorders | 5/100 | 1/50 | 7/101 | 6/99 |
| Oral candidiasisInfections and infestations | 0/100 | 0/50 | 0/101 | 6/99 |
| VomitingGastrointestinal disorders | 1/100 | 3/50 | 4/101 | 4/99 |
| CystitisInfections and infestations | 3/100 | 3/50 | 2/101 | 2/99 |
Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.
| Age, Continuous(Years) | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg | Total |
|---|---|---|---|---|---|
| Mean | 42.5 ± 9.60 | 41.5 ± 11.79 | 42.8 ± 12.71 | 41.0 ± 11.47 | 42.0 ± 11.37 |
| Sex: Female, Male(Participants) | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg | Total |
|---|---|---|---|---|---|
| Female | 94 | 45 | 97 | 91 | 327 |
| Male | 6 | 5 | 4 | 8 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 29 | 17 | 34 | 35 | 115 |
| Not Hispanic or Latino | 71 | 32 | 67 | 62 | 232 |
| Unknown or Not Reported | 0 | 1 | 0 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | PF-06700841 15 mg | PF-06700841 30 mg | PF-06700841 45 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 7 | 2 | 11 |
| Asian | 14 | 9 | 11 | 13 | 47 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 6 | 7 | 23 |
| White | 71 | 31 | 69 | 68 | 239 |
| More than one race | 2 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 5 | 6 | 8 | 9 | 28 |
Showing the first 100 of 164 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2019 to primary completion in Oct 2023, 53 months.
Results were first posted in Sep 2024, 11 months after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 53 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841
Lupus Erythematosus, Systemic →